



Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease- 19 (COVID- 19)

Salma Bessalah¹ · Samira Jebahi² · Naceur Mejri² · Imed Salhi¹ · Touhami Khorchani¹ · Mohamed Hammadi¹

Received: 16 June 2020 / Accepted: 6 January 2021
© King Abdulaziz City for Science and Technology 2021

Abstract

In this paper, we focus on the camelid nanobodies as a revolutionary therapy that can guide efforts to discover new drugs for Coronavirus disease (COVID-19). The small size property makes nanobodies capable of penetrating efficiently into tissues and recognizing cryptic antigens. Strong antigen affinity and stability in the gastrointestinal tract allow them to be used via oral administration. In fact, the use of nanobodies as inhalant can be directly delivered to the target organ, conferring high pulmonary drug concentrations and low systemic drug concentrations and minimal systemic side effects. For that, nanobodies are referred as a class of next-generation antibodies. Nanobodies permit the construction of multivalent formats that may achieve ultra-high neutralization potency and then may prevent mutational escape and can neutralize a wide range of SARS-CoV-2 variants. Due to their distinctive characteristics, nanobodies can be of great use in the development of promising treatment or preventive strategies against SARS-CoV-2 infection. In this review, the state-of-the-art of camel nanobodies design strategies against the virus including SARS-CoV-2 are critically summarized. The application of general nanotechnology was also discussed to mitigate and control emerging SARS-CoV-2 infection.

Keywords Antibodies engineering · Coronavirus disease (COVID-19) · Heavy chain antibodies · Pandemic · Single- domain antibody

Introduction

The coronavirus disease 2019 (COVID-19) is spreading rapidly since its first appearance in Wuhan, China, in December 2019. The occurrence of COVID-19 has been reported from more than 200 countries worldwide. On 16 December 2020, the number of confirmed cases has reached 73,476,721

including 1,635,464 deaths (<https://coronavirus.jhu.edu/map.html>). Coronavirus was referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and belongs to the beta-CoV genus of the Coronaviridae family (Lu et al. 2020). Phylogenetic analysis showed that SARS-CoV-2 genome has shared the highest nucleotide sequence identity to severe acute respiratory syndrome coronavirus

✉ Salma Bessalah
bessalahsalma@yahoo.fr
https://scholar.google.com/scholar?hl=fr&as_sdt=0%2C5&q=salma+bessalah&btnG=

Samira Jebahi
jbahisamira@yahoo.fr
https://scholar.google.com/scholar?hl=fr&as_sdt=0%2C5&q=samira+jbahi&btnG=&oq=samira+jbahi

Naceur Mejri
mejri.naceur@gmail.com
https://scholar.google.com/scholar?hl=fr&as_sdt=0%2C5&q=naceur+mejri&btnG=

Imed Salhi
imedsalhi@gmail.com
https://scholar.google.com/scholar?hl=fr&as_sdt=0%2C5&q=imed+salhi&btnG=

Touhami Khorchani
touha2009@gmail.com
https://scholar.google.com/scholar?hl=fr&as_sdt=0,5&q=touhami+khorchani

Mohamed Hammadi
mhammadi70@gmail.com
https://scholar.google.com/scholar?hl=fr&as_sdt=0%2C5&q=mohamed+hammadi&btnG=

¹ Livestock and Wildlife Laboratory, Arid Lands Institute (I.R.A), University of Gabès, 4119 Médenine, Tunisia

² Laboratory on Energy and Matter for Nuclear Sciences Development (LR16CNSTN02), National Centre for Nuclear Sciences and Technologies, Sidi Thabet Technopark, 2020 Sidi Thabet, Tunisia, Pole technologique, BP 72, 2020 Sidi Thabet, Tunisia